StreetInsider.com News Articles

Intellia short interest rises most among biotech stocks in latest period - Baird

Tue, 12 May 2026 09:58:46 -0400

Investing.com -- Baird's latest biotech short interest update shows Intellia Therapeutics (NASDAQ:NTLA) recorded the highest absolute increase in short interest over the past two weeks, rising 4 percentage points to 39% from 35%, according to data as of April 30, 2026.

Denali Therapeutics (NASDAQ:DNTH) saw the largest absolute decrease in short interest, dropping 12 percentage points to 13% from 25% during the same period.

Eight stocks in Baird's biotech coverage have short interest exceeding 20% of float. NTLA, Iovance Biotherapeutics (NASDAQ:IOVA), CRISPR Therapeutics (NASDAQ:CRSP), and Karyopharm Therapeutics (NASDAQ:KPTI) are the four most heavily shorted names across the firm's biotech coverage, according to

Intellia short interest rises most among biotech stocks in latest period - Baird

Tue, 12 May 2026 09:58:46 -0400

Denali Therapeutics (NASDAQ:DNTH) saw the largest absolute decrease in short interest, dropping 12 percentage points to 13% from 25% during the same period.

Intellia short interest rises most among biotech stocks in latest period - Baird

Tue, 12 May 2026 09:58:46 -0400

Denali Therapeutics (NASDAQ:DNTH) saw the largest absolute decrease in short interest, dropping 12 percentage points to 13% from 25% during the same period.

Intellia short interest rises most among biotech stocks in latest period - Baird

Tue, 12 May 2026 09:58:46 -0400

Denali Therapeutics (NASDAQ:DNTH) saw the largest absolute decrease in short interest, dropping 12 percentage points to 13% from 25% during the same period.

Intellia short interest rises most among biotech stocks in latest period - Baird

Tue, 12 May 2026 09:58:46 -0400

Denali Therapeutics (NASDAQ:DNTH) saw the largest absolute decrease in short interest, dropping 12 percentage points to 13% from 25% during the same period.

Intellia short interest rises most among biotech stocks in latest period - Baird

Tue, 12 May 2026 09:58:46 -0400

Denali Therapeutics (NASDAQ:DNTH) saw the largest absolute decrease in short interest, dropping 12 percentage points to 13% from 25% during the same period.

Biotech funds see $1.5 billion outflows in latest week says Raymond James

Thu, 07 May 2026 15:04:10 -0400

Investing.com -- Healthcare and biotech-focused mutual funds and ETFs recorded net outflows of $1.5 billion for the week ending Wednesday, according to data from Raymond James.

The outflows represented a 1.53% decrease in assets across 130 funds managing approximately $99.5 billion. Year-to-date net outflows have reached $1.98 billion.

This marks the second consecutive week of outflows from the sector.

The breadth ratio, which measures the number of funds experiencing inflows divided by those seeing outflows, increased to 0.48 from 0.45 the previous week.

Raymond James noted that when the breadth ratio reaches 0.3, the biotech sector has historically rallied by an average of 17.5%

Biotech funds see $1.5 billion outflows in latest week says Raymond James

Thu, 07 May 2026 15:04:10 -0400

Investing.com -- Healthcare and biotech-focused mutual funds and ETFs recorded net outflows of $1.5 billion for the week ending Wednesday, according to data from Raymond James.

The outflows represented a 1.53% decrease in assets across 130 funds managing approximately $99.5 billion. Year-to-date net outflows have reached $1.98 billion.

This marks the second consecutive week of outflows from the sector.

The breadth ratio, which measures the number of funds experiencing inflows divided by those seeing outflows, increased to 0.48 from 0.45 the previous week.

Raymond James noted that when the breadth ratio reaches 0.3, the biotech sector has historically rallied by an average of 17.5%

Increasing unusual put option volume: ALDX SMMT FIS KLAR WHR LNC UL IGV XBI SGHC DLR SOLT

Tue, 24 Feb 2026 10:12:58 -0400

Increasing unusual put option volume: ALDX SMMT FIS KLAR WHR LNC UL IGV XBI SGHC DLR SOLT

Biotech stocks: Q3 earnings preview

Sun, 12 Oct 2025 15:00:00 -0400

RBC Capital Markets is out with its preview into Q3 earnings of Biotech stocks, in which the firm’s analysts noted improving sentiment and said the quarter will likely be solid with very few disappointments.

Launches of several companies including Alynylam Pharmaceuticals (NASDAQ: ALNY) and Ascendis Pharma (NASDAQ: ASND) remain strong, and others are starting to pick up, the analysts highlighted. Also, mergers and acquisitions (M&A) activity is starting to pick up again, even if at lesser premiums than last year. And third, the firm highlighted positive data from trials.